Literature DB >> 28087642

STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Yukihiro Otaka1,2, Susumu Rokudai1,3, Kyoichi Kaira4, Michiru Fujieda1, Ikuko Horikoshi1, Reika Iwakawa-Kawabata1,5, Shinji Yoshiyama5, Takehiko Yokobori1,5, Yoichi Ohtaki6, Kimihiro Shimizu6, Tetsunari Oyama7, Jun'ichi Tamura2, Carol Prives3, Masahiko Nishiyama1,5.   

Abstract

Purpose: Expression of the ΔN isoform of p63 (ΔNp63) is a diagnostic marker highly specific for lung squamous cell carcinoma (SCC). We previously found that Syntaxin Binding Protein 4 (STXBP4) regulates ΔNp63 ubiquitination, suggesting that STXBP4 may also be an SCC biomarker. To address this issue, we investigated the role of STXBP4 expression in SCC biology and the impact of STXBP4 expression on SCC prognosis.Experimental Design: We carried out a clinicopathologic analysis of STXBP4 expression in 87 lung SCC patients. Whole transcriptome analysis using RNA-seq was performed in STXBP4-positive and STXBP4-negative tumors of lung SCC. Soft-agar assay and xenograft assay were performed using overexpressing or knockdown SCC cells.
Results: Significantly higher levels of STXBP4 expression were correlated with accumulations of ΔNp63 in clinical lung SCC specimens (Spearman rank correlation ρ = 0.219). Notably, STXBP4-positive tumors correlated with three important clinical parameters: T factor (P < 0.001), disease stage (P = 0.030), and pleural involvement (P = 0.028). Whole transcriptome sequencing followed by pathway analysis indicated that STXBP4 is involved in functional gene networks that regulate cell growth, proliferation, cell death, and survival in cancer. Platelet-derived growth factor receptor alpha (PDGFRα) was a key downstream mediator of STXBP4 function. In line with this, shRNA mediated STXBP4 and PDGFRA knockdown suppressed tumor growth in soft-agar and xenograft assays.Conclusions: STXBP4 plays a crucial role in driving SCC growth and is an independent prognostic factor for predicting worse outcome in lung SCC. These data suggest that STXBP4 is a relevant therapeutic target for patients with lung SCC. Clin Cancer Res; 23(13); 3442-52. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28087642      PMCID: PMC5496791          DOI: 10.1158/1078-0432.CCR-16-1815

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  p63 is a p53 homologue required for limb and epidermal morphogenesis.

Authors:  A A Mills; B Zheng; X J Wang; H Vogel; D R Roop; A Bradley
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

2.  RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage.

Authors:  Alexey Fomenkov; Rachel Zangen; Yi-Ping Huang; Motonobu Osada; Zhongmin Guo; Tanya Fomenkov; Barry Trink; David Sidransky; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2004-10-06       Impact factor: 4.534

3.  Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.

Authors:  Yingchun Li; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

4.  MOZ increases p53 acetylation and premature senescence through its complex formation with PML.

Authors:  Susumu Rokudai; Oleg Laptenko; Suzzette M Arnal; Yoichi Taya; Issay Kitabayashi; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

5.  Association of STXBP4/COX11 rs6504950 (G>A) polymorphism with breast cancer risk: evidence from 17,960 cases and 22,713 controls.

Authors:  Lin Tang; Jing Xu; Feng Wei; Li Wang; Wei-Wei Nie; Long-Bang Chen; Xiao-Xiang Guan
Journal:  Arch Med Res       Date:  2012-08-03       Impact factor: 2.235

6.  Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma.

Authors:  Kyoichi Kaira; Yutaka Sunose; Kazuhisa Arakawa; Noriaki Sunaga; Kimihiro Shimizu; Hideyuki Tominaga; Noboru Oriuchi; Shushi Nagamori; Yoshikatsu Kanai; Tetsunari Oyama; Izumi Takeyoshi
Journal:  Histopathology       Date:  2014-12-23       Impact factor: 5.087

7.  Synip: a novel insulin-regulated syntaxin 4-binding protein mediating GLUT4 translocation in adipocytes.

Authors:  J Min; S Okada; M Kanzaki; J S Elmendorf; K J Coker; B P Ceresa; L J Syu; Y Noda; A R Saltiel; J E Pessin
Journal:  Mol Cell       Date:  1999-06       Impact factor: 17.970

8.  Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63.

Authors:  Pascal H G Duijf; Kaate R J Vanmolkot; Peter Propping; Waltraut Friedl; Elmar Krieger; Frank McKeon; Volker Dötsch; Han G Brunner; Hans van Bokhoven
Journal:  Hum Mol Genet       Date:  2002-04-01       Impact factor: 6.150

9.  Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma.

Authors:  Koichiro Higashikawa; Shingo Yoneda; Kei Tobiume; Masayuki Taki; Hideo Shigeishi; Nobuyuki Kamata
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 10.  Targeting the PDGF signaling pathway in tumor treatment.

Authors:  Carl-Henrik Heldin
Journal:  Cell Commun Signal       Date:  2013-12-20       Impact factor: 5.712

View more
  9 in total

1.  STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis.

Authors:  Susumu Rokudai; Yingchun Li; Yukihiro Otaka; Michiru Fujieda; David M Owens; Angela M Christiano; Masahiko Nishiyama; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

2.  Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents.

Authors:  Yumiko Kawata-Shimamura; Hidetaka Eguchi; Reika Kawabata-Iwakawa; Mitsuhiko Nakahira; Yasushi Okazaki; Tetsuya Yoda; Reidar Grénman; Masashi Sugasawa; Masahiko Nishiyama
Journal:  BMC Cancer       Date:  2022-07-16       Impact factor: 4.638

3.  Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis.

Authors:  Ying Zhu; Yongyue Wei; Ruyang Zhang; Xuesi Dong; Sipeng Shen; Yang Zhao; Jianling Bai; Demetrius Albanes; Neil E Caporaso; Maria Teresa Landi; Bin Zhu; Stephen J Chanock; Fangyi Gu; Stephen Lam; Ming-Sound Tsao; Frances A Shepherd; Adonina Tardon; Ana Fernández-Somoano; Guillermo Fernandez-Tardon; Chu Chen; Matthew J Barnett; Jennifer Doherty; Stig E Bojesen; Mattias Johansson; Paul Brennan; James D McKay; Robert Carreras-Torres; Thomas Muley; Angela Risch; Heunz-Erich Wichmann; Heike Bickeboeller; Albert Rosenberger; Gad Rennert; Walid Saliba; Susanne M Arnold; John K Field; Michael P A Davies; Michael W Marcus; Xifeng Wu; Yuanqing Ye; Loic Le Marchand; Lynne R Wilkens; Olle Melander; Jonas Manjer; Hans Brunnström; Rayjean J Hung; Geoffrey Liu; Yonathan Brhane; Linda Kachuri; Angeline S Andrew; Eric J Duell; Lambertus A Kiemeney; Erik Hfm van der Heijden; Aage Haugen; Shanbeh Zienolddiny; Vidar Skaug; Kjell Grankvist; Mikael Johansson; Penella J Woll; Angela Cox; Fiona Taylor; Dawn M Teare; Philip Lazarus; Matthew B Schabath; Melinda C Aldrich; Richard S Houlston; John McLaughlin; Victoria L Stevens; Hongbing Shen; Zhibin Hu; Juncheng Dai; Christopher I Amos; Younghun Han; Dakai Zhu; Gary E Goodman; Feng Chen; David C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-30       Impact factor: 4.254

Review 4.  p63-related signaling at a glance.

Authors:  Matthew L Fisher; Seamus Balinth; Alea A Mills
Journal:  J Cell Sci       Date:  2020-09-11       Impact factor: 5.285

5.  Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.

Authors:  Rebecca E Vargas; Vy Thuy Duong; Han Han; Albert Paul Ta; Yuxuan Chen; Shiji Zhao; Bing Yang; Gayoung Seo; Kimberly Chuc; Sunwoo Oh; Amal El Ali; Olga V Razorenova; Junjie Chen; Ray Luo; Xu Li; Wenqi Wang
Journal:  EMBO J       Date:  2019-11-29       Impact factor: 11.598

Review 6.  TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development.

Authors:  Mei Yi; Yixin Tan; Li Wang; Jing Cai; Xiaoling Li; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Xiayu Li; Pingqing Tan; Bo Xiang
Journal:  Cell Mol Life Sci       Date:  2020-05-23       Impact factor: 9.261

7.  Elevated expression of ΔNp63 in advanced esophageal squamous cell carcinoma.

Authors:  Yuji Kumakura; Susumu Rokudai; Misaki Iijima; Bolag Altan; Tomonori Yoshida; Halin Bao; Takehiko Yokobori; Makoto Sakai; Makoto Sohda; Tatsuya Miyazaki; Masahiko Nishiyama; Hiroyuki Kuwano
Journal:  Cancer Sci       Date:  2017-10-03       Impact factor: 6.716

8.  Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling.

Authors:  Eisuke Horigome; Michiru Fujieda; Tadashi Handa; Ayaka Katayama; Masashi Ito; Ami Ichihara; Daiki Tanaka; Navchaa Gombodorj; Shinji Yoshiyama; Arito Yamane; Keiichi Yamada; Jun Horiguchi; Kazuo Shinozuka; Tetsunari Oyama; Masahiko Nishiyama; Susumu Rokudai
Journal:  Oncotarget       Date:  2018-10-02

9.  Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.

Authors:  Erkhem-Ochir Bilguun; Kyoichi Kaira; Reika Kawabata-Iwakawa; Susumu Rokudai; Kimihiro Shimizu; Takehiko Yokobori; Tetsunari Oyama; Ken Shirabe; Masahiko Nishiyama
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.